

#5

SHEET 1 OF 5

INFORMATION DISCLOSURE CITATION			ATTORNEY'S DKT NO. 002010-685		APPLICATION NO. 09/882,777		
PTO-1449			APPLICANT Audia, et al.		FILING DATE June 14, 2001		
			GROUP 1624				
<b>U.S. PATENT DOCUMENTS</b>							
EXAMINER'S INITIALS	PATENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE	
B.K.	3,598,859	8/10/71	Yates, et al.				
	3,657,341	4/18/72	Thorne				
	4,080,449	3/21/78	Croisier, et al.				
	4,477,464	10/16/84	Slade, et al.				
	4,666,829	5/19/87	Glennner, et al.				
	4,977,168	12/11/90	Bernat, et al.				
	5,238,932	8/24/93	Flynn, et al.				
	5,283,241	2/1/94	Bochis, et al.				
	5,284,841	2/8/94	Chu, et al.				
	5,324,726	6/28/94	Bock, et al.				
	5,360,802	11/1/94	Chambers, et al.				
	5,420,271	5/30/95	Warshawsky, et al.				
	5,478,857	12/26/95	Clemens, et al.				
	5,556,969	9/17/96	Chambers, et al.				
	5,633,251	5/27/97	Claremon, et al.				
	5,658,901	8/19/97	Claremon, et al.				
	5,712,397	1/27/98	Esser, et al.				
	5,770,573	6/23/98	Arrhenius, et al.				
<b>FOREIGN PATENT DOCUMENTS</b>							
EXAMINER'S INITIALS	PATENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	Translation	
						Yes	No
B.K.	0 061 187	9/29/82	Europe				
	0 167 919	1/15/86	Europe				
	0 284 256	9/28/88	Europe				
	0 349 949	1/10/90	Europe				
	0 376 849	7/4/90	Europe (Abstract in English)				

<b>INFORMATION DISCLOSURE CITATION</b>  PTO-1449	ATTORNEY'S DKT NO. 002010-685	APPLICATION NO. 09/882,777
	APPLICANT Audia, et al.	
	FILING DATE June 14, 2001	GROUP 1624

D.K.	0 434 360	6/26/91	Europe				
	0 434 364	6/26/91	Europe				
	0 434 369	6/26/91	Europe				
	0 490 590	6/17/92	Europe				
	0 514 133	11/19/92	Europe				
	0 523 845	1/20/93	Europe				
	0 549 039	6/30/93	Europe				
	0 647 632	4/12/95	Europe				
	0 652 009	8/16/95	Europe				
	0 667 344	8/16/95	Europe (Abstract in English)				
	0 677 517	10/18/95	Europe				
	0 732 399	9/18/96	Europe				
	0 778 266	11/6/97	Europe				
	1 519 495	7/6/78	Great Britain				
	1 573 931	8/18/80	Great Britain				
	2 272 439	5/18/94	Great Britain				
	2 290 788	1/10/96	Great Britain				
	04210967	8/3/94	Japan (Abstract in English)				
	06145148	5/24/94	Japan (Abstract in English)				
	07304770	11/21/95	Japan (Abstract in English)				
	10072444	3/17/98	Japan (Abstract in English)				
	92/01683	2/6/92	WIPO				
	92/16524	10/1/92	WIPO				
	93/19052	9/30/93	WIPO				
	93/19063	9/30/93	WIPO				
	94/05693	3/17/94	WIPO				
	94/04531	3/3/94	WIPO				
	94/07486	4/14/94	WIPO				
V	94/10569	5/11/94	WIPO				

RECEIVED


SEP 2 2001

TECH CENTER 1600/29

RECEIVED

NOV 23 2001

TECH CENTER 1600/2000



<b>INFORMATION DISCLOSURE CITATION</b>  PTO-1449	ATTORNEY'S DKT NO. 002010-685	APPLICATION NO. 09/882,777
	APPLICANT Audia, et al.	
	FILING DATE June 14, 2001	GROUP 1624

B.K.	95/03289	2/2/95	WIPO		RECEIVED
	95/03290	2/2/95	WIPO		SEP 21 2001
	95/09838	4/13/95	WIPO		TECH CENTER 1600/2900
	95/14671	6/1/95	WIPO		
	95/21840	8/17/95	WIPO		
	95/23810	9/8/95	WIPO		
	95/25118	9/21/95	WIPO		RECEIVED
	95/32191	11/30/95	WIPO		NOV 23 2001
	96/05839	2/29/96	WIPO		TECH CENTER 1600/2900
	96/16981	6/6/96	WIPO		
	96/20725	7/11/96	WIPO		
	96/22966	8/1/96	WIPO		
	96/40146	12/19/96	WIPO		
	96/40653	12/19/96	WIPO		
	96/40654	12/19/96	WIPO		
	96/40655	12/19/96	WIPO		
	96/40656	12/19/96	WIPO		
	97/30072	8/21/97	WIPO		
	97/38705	10/23/97	WIPO		
	98/00405	1/8/98	WIPO		
	98/25930	6/18/98	WIPO		
	98/28268	7/2/98	WIPO		
	98/38177	9/3/98	WIPO		
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)					
B.K.	Aquino, et al. "Discovery of 1,5-Benzodiazepines with Peripheral Cholecystokinin (CCK-A) Receptor Agonist Activity. 1. Optimization of the Agonist "Trigger." <i>J. Med. Chem.</i> 39: 562-569 (1996).				

<b>INFORMATION DISCLOSURE CITATION</b>  PTO-1449	ATTORNEY'S DKT NO. 002010-685	APPLICATION NO. 09/882,777
	APPLICANT Audia, et al.	
	FILING DATE June 14, 2001	GROUP 1624

B.K.	Bock, et al. "Selective Non-Peptide Ligands for an Accommodating Peptide Receptor. Imidazobenzodiazepines as Potent Cholecystokinin Type B Receptor Antagonists." <i>Bioorg. and Med. Chem. Lett.</i> 2(9):987-998 (1994).
	Bock, et al. "Synthesis and Resolution of 3-Amino-1,3-dihydro-5-phenyl-2H-1,4-benzodiazepin-2-ones." <i>J. Org. Chem.</i> 52: 3232-3239 (1987).
	Bock, et al. "An Expedient Synthesis of 3-Amino-1,3-Dihydro-5-Phenyl-2H-1,4-Benzodiazepin-2-one." <i>Tet. Lett.</i> 28(9): 939-942 (1987).
	Chambers, et al. L-708,474: the C5-Cyclohexyl Analogue of L-365,260, A Selective High Affinity Ligand for the CCKB/Gastrin Receptor." <i>Bioorg. and Med. Chem. Letts.</i> 3(10):1919-1924 (1993).
	Chartier-Harlin, et al. "Early-onset Alzheimer's disease caused by mutations at codon 717 of the $\beta$ -Amyloid precursor protein gene." <i>Nature.</i> 353: 844-846 (1991).
	Citron, et al. "Mutation of the $\beta$ -amyloid precursor protein in familial Alzheimer's disease increases $\beta$ -amyloid protein production." <i>Nature</i> 360:672-674 (1992).
	Cordell. "B-Amyloid Formation as a Potential Therapeutic Target for Alzheimer's Disease." <i>Ann. Rev. Pharmacol. Toxicol.</i> 34:69-89 (1994).
	Evans, et al. "Methods for Drug Discovery: Development of Potent, Selective Orally Effective Cholecystokinin Antagonists." <i>J. Med. Chem.</i> 31:2235-2246 (1988).
	Evans, et al. "Molecular Mimicry and the Design of Peptidomimetics." <i>Molecular Mimicry in Health and Disease.</i> (A. Lernmark, et al., eds.) Elsevier Science Publishers B.v. (Biomedical Division) (1988) pp. 23-34.
	Finizia, et al. "Synthesis and Evaluation of Novel 1,5-Benzodiazepines as potent and selective CCK-B Ligands, Effect of the Substitution of the N-5 Phenyl with Alkyl Groups." <i>Bioorg. &amp; Medicinal Chemistry Letters.</i> 6(24):2957-2962 (1996).
	Glenner, et al. "Alzheimer's disease: Initial Report of the Purification and Characterization of a Novel Cerebrovascular Amyloid Protein." <i>Biochem. Biophys. Res. Commun.</i> 120(3): 885-890 (1984).
	Goate, et al. "Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease." <i>Nature.</i> 349: 704-706 (1991).
	Hirst, et al. "Discovery of 1,5-Benzodiazepines with Peripheral Cholecystokinin (CCK-A) Receptor Agonists Activity (II): Optimization of the C3 Amino Substituent." <i>J. Med. Chem.</i> 39: 5236-5245 (1996).
	Hofmann, et al. "Interactions of Benzodiazepine Derivatives with Annexins." <i>J. Biol. Chem.</i> 273(5):2885-2894 (1998).
	Johnson-Wood, et al. "Amyloid precursor protein processing and $A\beta_{42}$ deposition in a transgenic mouse model of Alzheimer's disease." <i>PNAS USA.</i> 94: 1550-1555 (1997).
	Ksander, G.M., et al. "Dual Angiotensin Converting Enzyme/Thromboxane Synthase Inhibitors." <i>J. Med. Chem.</i> 37: 1823-1832 (1994).
	Lowe, et al. "A Water Soluble Benzazepine Cholecystokinin-B-Receptor Antagonist." <i>Bioorg. and Med. Chem. Lett.</i> 5(17): 1933-1936 (1995).
↓	Lowe, et al. "5-Phenyl-3-ureidobenzazepin-2-ones as Cholecystokinin-B Receptor Antagonists." <i>J. Med. Chem.</i> 37: 3789-3811 (1994).

RECEIVED

SHEET 5 5

TECH CENTER 1600/2900  
SEP 21 2001

<p><b>INFORMATION DISCLOSURE CITATION</b></p> <p>PTO-1449</p>	<p>ATTORNEY'S DKT NO. 002010-685</p>	<p>APPLICATION NO. 09/882,777</p>
	<p>APPLICANT Audia, et al.</p>	
	<p>FILING DATE June 14, 2001</p>	<p>GROUP 1624</p>

<p>D.K.</p>	<p>Mullan, et al. "A pathogenic mutation for probable Alzheimer's disease in the APP gene at the N-terminus of <math>\beta</math>-amyloid." <i>Nature Genet.</i> 1: 345-347 (1992).</p>
	<p>Murrell, et al. "A Mutation in the Amyloid Precursor Protein Associate with Hereditary Alzheimer's Disease." <i>Science.</i> 254: 97-99 (1991).</p>
	<p>Papadopoulos, et al. Anodic Oxidation of N-Acyl and N-Alkoxycarbonyl Dipeptide Esters as a Key Step for the Formation of Chiral Heterocyclic Synthetic Building Blocks." <i>Tetrahedron</i> 47(4/5):563-572 (1991).</p>
<p>DIPE CITY SEP 19 2001 MAR 19 2001</p>	<p>Patel, et al. "Biological Properties of the Benzodiazepine Amidine Derivative L-740,093, a Cholecystokinin-B/Gastrin Receptor Antagonist with High Affinity in vitro and High Potency in vivo." <i>Molecular Pharmacology.</i> 46:943-948 (1994).</p>
	<p>Rittle, et al. "A New Amine Resolution Method and its Application to 3-Aminobenzodiazepines." <i>Tet. Lets.</i> 28(5):521-522 (1987).</p>
	<p>Satoh, et al. "New 1,4-Benzodiazepine-2-one Derivatives as Gastrin/Cholecystokinin-B Antagonists." <i>Chem. Pharm. Bull.</i> 43(12): 2159-2167 (1995).</p>
<p>RECEIVED NOV 23 2001</p>	<p>Selkoe, et al. "Amyloid Protein and Alzheimer's Disease." <i>Scientific American.</i> 68-78 (1991).</p>
<p>TECH CENTER 1600/2900</p>	<p>Selkoe, et al. "The Molecular Pathology of Alzheimer's Disease." <i>Neuron.</i> 6:487-498 (1991).</p>
	<p>Seeborg, et al. "Design, Synthesis, and Evolution of a Novel, Selective, and Orally Bioavailable Class of Thrombin Inhibitors: P1-Argininal Derivatives Incorporating P3-P4 Lactam Sulfoamide Moieties." <i>J. Med. Chem.</i> 39: 4531-4536 (1996).</p>
	<p>Semple, et al. "A Facile Large Scale Synthesis of Optically Active 3-Amino-5-(2-Pyridyl)-1,4-Benzodiazepin-2-One Derivatives." <i>Synthetic Communications.</i> 26(4): 721-727 (1996).</p>
	<p>Seubert, et al. "Isolation and quantification of soluble Alzheimer's peptide from biological fluids." <i>Nature.</i> 359: 325-327 (1992).</p>
	<p>Sherrill, et al. "An Improved Synthesis and Resolution of 3-Amino-1,3 dihydro-5-phenyl-2H-1,4-benzodiazepin-2-ones." <i>J. Org. Chem.</i> 60:730-734 (1995).</p>
	<p>Showell, et al. "High Affinity and Potent, Water-Soluble 5-Amino-1,4-Benzodiazepine CCKB/Gastrin Receptor Antagonists Containing a Cationic Solubilizing Group." <i>J. Med. Chem.</i> 37:719-721 (1994).</p>
	<p>Smith, et al. "<math>\beta</math>-APP Processing as a Therapeutic Target for Alzheimer's Disease." <i>Current Pharmaceutical Design.</i> 3:439-445 (1997).</p>
	<p>Van Niel, et al. "CCKB Selective Receptor Ligands: Novel 1,3,5-Trisubstituted Benzazepin-2-ones." <i>Bioorganic &amp; Medicinal Chemistry Letters.</i> 5(13):1421-1426 (1995).</p>
<p>↓</p>	<p>Varnavas, et al. "Synthesis of New Benzodiazepine Derivatives as Potential Cholecystokinin Antagonists." <i>Il Farmaco.</i> 46(2):391-401 (1991).</p>
<p>EXAMINER</p>	<p>DATE CONSIDERED 6/15/04</p>

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.